Patches marketed as ‘GLP-1 patches’ actually do not contain GLP-1 active ingredients, such as semaglutide or tirzepatide. Currently, no ‘GLP-1 patches’ are approved by the Food and Drug Administration ...

If you watched the Super Bowl in 2026, you likely saw Serena Williams share her weight loss journey on GLP-1 medications in a commercial. Like millions of others around the country, if you’ve ever ...

Some people’s genes influence how much weight they will lose and what side effects they will experience while taking GLP-1 drugs, such as Ozempic and Zepbound. “The results that we got made perfect ...

The financial impact of rising GLP-1 usage extends far beyond Big Pharma. For users of weight-loss drugs, costs can snowball, with bills for supplements, trainers, and clothing piling up. Here are ...

23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 ...

Of all the millions of people who have tried weight-loss drugs such as Wegovy and Zepbound, nearly one in four people don’t respond to treatment. They lose little weight, or none at all, and see few ...

Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is ...

Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella ...

Wall Street has placed a big bet on GLP-1 drugs. When Walmart’s U.S. CEO, John Furner, told Bloomberg in October 2023 that customers on Ozempic were buying “slightly less calories,” packaged-food ...

GLP-1 medications are now available as both pills and injections, offering more options for weight loss treatment. The two forms work similarly and have comparable results, but differ in dosing, ...

The FDA has clarified its policies regarding GLP-1s, stating that pharmacies must stop compounding GLP-1 drugs once branded versions are removed from the agency’s shortage list, signaling a narrower ...